These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 18802703)

  • 21. The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes.
    Aparicio-Siegmund S; Garbers Y; Flynn CM; Waetzig GH; Gouni-Berthold I; Krone W; Berthold HK; Laudes M; Rose-John S; Garbers C
    Am J Physiol Endocrinol Metab; 2019 Aug; 317(2):E411-E420. PubMed ID: 31237452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis.
    Mees ST; Toellner S; Marx K; Faendrich F; Kallen KJ; Schroeder J; Haier J; Kahlke V
    J Surg Res; 2009 Dec; 157(2):235-42. PubMed ID: 19589542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The soluble form of the IL-6 receptor (sIL-6R alpha) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R alpha-induced AIDS-KS cell growth.
    Murakami-Mori K; Taga T; Kishimoto T; Nakamura S
    Int Immunol; 1996 Apr; 8(4):595-602. PubMed ID: 8722639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus.
    Aoki Y; Narazaki M; Kishimoto T; Tosato G
    Blood; 2001 Nov; 98(10):3042-9. PubMed ID: 11698289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alternative intronic polyadenylation generates the interleukin-6 trans-signaling inhibitor sgp130-E10.
    Sommer J; Garbers C; Wolf J; Trad A; Moll JM; Sack M; Fischer R; Grötzinger J; Waetzig GH; Floss DM; Scheller J
    J Biol Chem; 2014 Aug; 289(32):22140-50. PubMed ID: 24973212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measurements of IL-6, soluble IL-6 receptor and soluble gp130 in sera of B-cell lymphoma patients. Does viscum album treatment affect these parameters?
    Kovacs E; Kuehn JJ
    Biomed Pharmacother; 2002 May; 56(3):152-8. PubMed ID: 12046687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a monoclonal antibody-based enzyme-linked immunoabsorbent assay for the binding of gp130 to the IL-6/IL-6R complex and its competitive inhibition.
    Scheller J; Kovaleva M; Rabe B; Eichler J; Kallen KJ; Rose-John S
    J Immunol Methods; 2004 Aug; 291(1-2):93-100. PubMed ID: 15345308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6.
    Gaillard JP; Mani JC; Liautard J; Klein B; Brochier J
    Eur Cytokine Netw; 1999 Mar; 10(1):43-8. PubMed ID: 10210772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional expression of a biologically active fragment of soluble gp130 as an ELP-fusion protein in transgenic plants: purification via inverse transition cycling.
    Lin M; Rose-John S; Grötzinger J; Conrad U; Scheller J
    Biochem J; 2006 Sep; 398(3):577-83. PubMed ID: 16716147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.
    Robak T; Wierzbowska A; Błasińska-Morawiec M; Korycka A; Błoński JZ
    Mediators Inflamm; 1999; 8(6):277-86. PubMed ID: 10815616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating interleukin 6 and soluble forms of its receptors in relation to resting energy expenditure in women with anorexia nervosa.
    Karczewska-Kupczewska M; Adamska A; Nikołajuk A; Otziomek E; Górska M; Kowalska I; Strączkowski M
    Clin Endocrinol (Oxf); 2013 Dec; 79(6):812-6. PubMed ID: 23199226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Determination of serum soluble interleukin-6 receptor and soluble gp130 levels in patient with pregnancy induced hypertension and its significance].
    Li Y; Wang Y; Qi L
    Zhonghua Fu Chan Ke Za Zhi; 2001 Jan; 36(1):18-9. PubMed ID: 11778537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Involvement of Spinal IL-6 Trans-Signaling in the Induction of Hyperexcitability of Deep Dorsal Horn Neurons by Spinal Tumor Necrosis Factor-Alpha.
    König C; Morch E; Eitner A; Möller C; Turnquist B; Schaible HG; Ebersberger A
    J Neurosci; 2016 Sep; 36(38):9782-91. PubMed ID: 27656018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence for altered activity of the IL-6 pathway in chronic rhinosinusitis with nasal polyps.
    Peters AT; Kato A; Zhang N; Conley DB; Suh L; Tancowny B; Carter D; Carr T; Radtke M; Hulse KE; Seshadri S; Chandra R; Grammer LC; Harris KE; Kern R; Schleimer RP
    J Allergy Clin Immunol; 2010 Feb; 125(2):397-403.e10. PubMed ID: 20159251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma.
    Zhuang PY; Wang JD; Tang ZH; Zhou XP; Quan ZW; Liu YB; Shen J
    BMC Cancer; 2015 Nov; 15():830. PubMed ID: 26525581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-6 receptor signaling. II. Bio-availability of interleukin-6 in serum.
    Gaillard J; Pugnière M; Tresca J; Mani J; Klein B; Brochier J
    Eur Cytokine Netw; 1999 Sep; 10(3):337-44. PubMed ID: 10477390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients.
    Kovacs E
    Biomed Pharmacother; 2001 Sep; 55(7):391-6. PubMed ID: 11669502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased levels of IL-6, sIL-6R, and sgp130 in the aqueous humor and serum of patients with diabetic retinopathy.
    Chen H; Zhang X; Liao N; Wen F
    Mol Vis; 2016; 22():1005-14. PubMed ID: 27563232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-6 trans-signaling is another pathway to upregulate Osteopontin.
    Uchibori T; Matsuda K; Shimodaira T; Sugano M; Uehara T; Honda T
    Cytokine; 2017 Feb; 90():88-95. PubMed ID: 27863335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.
    Nishimoto N; Terao K; Mima T; Nakahara H; Takagi N; Kakehi T
    Blood; 2008 Nov; 112(10):3959-64. PubMed ID: 18784373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.